medical device investing Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
medical device investing Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market
Contakt World Expands Commercial Portfolio Through Partnership Agreement with Portum for Health Screening, Vaccine Wallet, Vaccine Passport, and More
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
